John Paulson Paulson & Co
John Paulson is the founder of Paulson & Co., a firm that became world-famous for profits related to the 2007–2008 housing and credit crisis. Beyond that landmark trade, the firm has pursued merger arbitrage, event-driven, and opportunistic credit and equity strategies. Paulson remains one of the most recognized names in modern hedge fund history.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$260M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$67.9M |
| 2 |
AAMI
Acadian Asset Management
AAMI
|
+$53.8M |
| 3 |
SA
Seabridge Gold
SA
|
+$30.1M |
| 4 |
Equinox Gold
EQX
|
+$14.4M |
| 5 |
IAMGOLD
IAG
|
+$13.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.83% |
| 2 | Materials | 39.45% |
| 3 | Financials | 12.56% |
| 4 | Technology | 1.74% |
| 5 | Industrials | 1.42% |
Similar funds
John Paulson's Q3 2025 Portfolio in Review
As of Q3 2025, John Paulson held 15 positions worth $2.97B, up 48% from $2.01B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
John Paulson's Q3 2025 filing shows 1 increased, 2 reduced and 5 closed positions. The largest sale was Madrigal Pharmaceuticals, an estimated $67.9M.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 42% a quarter earlier, followed by Materials and Financials.
- John Paulson added most to Bausch Health in Q3 2025, an estimated $260M increase.
- John Paulson's biggest Q3 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $67.9M.
- John Paulson fully exited Seabridge Gold in Q3 2025, selling an estimated $30.1M.
- John Paulson's ten largest holdings make up 100% of its $2.97B portfolio in Q3 2025.
- John Paulson opened 0 new positions and closed 5 in Q3 2025.
- John Paulson's portfolio value rose 48% quarter-over-quarter to $2.97B.
Based on Paulson & Co's 13F filing for Q3 2025, filed 14 Nov 2025.